Ensign Peak Advisors
PNT

Ensign Peak Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Ensign Peak Advisors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,600
Closed -$105K – 2293
2022
Q3 		$105K Buy
13,600
+1,020
+8% +$8.66K ﹤0.01% 2083
2022
Q2 		$86K Hold
12,580
– – ﹤0.01% 1989
2022
Q1 		$100K Buy
12,580
+11,250
+846% +$71.4K ﹤0.01% 2031
2021
Q4 		$7K Buy
+1,330
New +$9.98K ﹤0.01% 2193

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ensign Peak Advisors's PNT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2022, closing a stake of 13,600 shares — an estimated $105K sold.

Ensign Peak Advisors first reported a position in PNT in Q4 2021 and held it in 4 quarters. The position peaked at $105K in Q3 2022. 109 funds tracked by Wall St. Rank hold PNT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 13,600 POINT Biopharma Global Inc. Common Stock shares in Q4 2022, an estimated $105K.
  • Ensign Peak Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $105K in Q3 2022.
  • 109 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.